The randomised controlled trial (RCT) PsyPal, coordinated by the University Medical Centre Groningen in the Netherlands, and in collaboration with HumanKindLabs, marks the firstever European grant to fund clinical research into psychedelic-assisted therapy.

The trial will investigate whether psilocybin therapy can help ease psychological and existential distress in patients suffering from one of four different progressive diseases: the lung condition chronic obstructive pulmonary disorder (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS, also known as MND), and atypical Parkinson’s disease (APD).

Professor Pehr Granqvist and Doctor Joel Gruneau Brulin, both at the Department of Psychology, Stockholm University, will be responsible for the spirituality- and attachment-related aspects of this project.

Read more

Psilocybin Therapy for Psychological Distress in Palliative Care Patients

Related journal article on this subject:

Cherniak, A. D., Gruneau Brulin, J., Mikulincer, M., Östlind, S., Carhart-Harris, R., & Granqvist, P. (2023). Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal. The International Journal for the Psychology of Religion, 33(4), 259-276. DOI: 10.1080/10508619.2022.2148061

Read more about Pehr Granqvist

Read more about Joel Gruneau Brulin

The partners in the research consortium are committed to upholding the highest ethical standards in clinical and research practices, as laid out in the Horizon Europe regulation. Furthermore, the consortium will adhere to any requirements or recommendations from ethics committees and regulatory authorities.

PoliticoDisclaimer - PsyPal is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.